Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

HitGen and Morphic Extend Drug Discovery Research Collaboration


HitGen Inc. (HitGen, 688222.SH) announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen's industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compounds that were exclusively licensed to Morphic.

Under the terms of the extended agreement, HitGen will use its platform technology, based on the design, synthesis and interrogation by selection of DELs to discover ligands for targets of interest to Morphic. Morphic will pay an assignment fee to HitGen in exchange for exclusive development and commercialization rights to compounds that achieve the criteria of the collaboration.

"The HitGen DEL platform provides chemical libraries that are excellent starting points for Morphic to expand the diversity of our compound collection targeting integrin receptors," commented Bruce Rogers, PhD, Chief Scientific Officer at Morphic Therapeutic Inc. "We are enthusiastic to expand this collaboration and build upon our previous work together."

"We are delighted to announce the extension of our collaboration with Morphic Therapeutic. The delivery of compounds under our initial agreement demonstrates the ability of our DEL platform to discover novel small molecule ligands against a variety of technically challenging targets. We look forward to further success in identifying small molecule compounds in our continued collaboration with Morphic," noted Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.

About HitGen Inc.

HitGen is a rapidly growing biotech company with headquarters based in Chengdu, China, with a subsidiary in the USA. HitGen has established an industry-leading platform for early-stage small molecule drug discovery centered on DNA encoded chemical libraries (DELs). HitGen's DELs include encoded syntheses for hundreds of billions of novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe, Australia and Asia to discover and develop the novel therapeutics of the future.

For more information, please call +86-28-85197385, +1 508-840 9646 or visit www.hitgen.com.


These press releases may also interest you

at 16:35
Phunware, Inc. (the "Company"), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, today announced financial results for its second quarter ended June 30, 2020, and...

at 16:30
Oblong, Inc. ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today announced financial results for the three months ended June 30, 2020. Financial Highlights Revenue of $2.8 million for the second...

at 16:30
The "Remote Patient Monitoring Systems Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. An increase in the chronic disease population, an increase in the aging population, and the demand...

at 16:15
QYOU Media    announced that the company and its Board of Directors have approved incentive Stock Option and Restricted Share Unit grants to employees and advisors in connection with work being done on behalf of the company.  The company will issue a...

at 16:15
MICT, Inc. , today announced financial results for the three months ended June 30, 2020. "We are very pleased and excited to have recently closed the acquisition of Global Fintech Holdings (GFH) and increased our stake in Micronet to majority owner,...

at 16:10
AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020. AgeX made strides with...



News published on 5 july 2020 at 21:05 and distributed by: